Fontolizumab

芳妥珠单抗

Report date: 2023/04/25 13:50:29

Base Information

Drug NameFontolizumab
Drug Alias NameAnti-interferon-gamma monoclonal antibody - Protein Design LabsSMART anti-gamma interferon antibodyHuZAF
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterferon gamma inhibitors
TargetsInterferon gamma
Therapy Area/IndicationsIntestinal DiseasesCrohn DiseaseColitis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPdl Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFacet Biotech Pvi LtdPdl Biopharma Inc
Active IndicationsN/A
Inactive IndicationsIntestinal DiseasesCrohn DiseaseColitis +[6] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG